Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Keryx Biopharmaceuticals Inc Announces Pricing Of Public Offering Of Common Stock

Wednesday, 30 Jan 2013 10:20pm EST 

Keryx Biopharmaceuticals Inc announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase 1,235,100 additional shares of common stock. The Company intend to use the net proceeds from the sale of the common stock to fund pre-launch/launch inventory build-up and select pre-commercial/ commercial activities related to Zerenex, and other general corporate purposes. J.P. Morgan Securities LLC is acting as sole book-running manager in the offering. The co-managers for the offering are Barclays Capital Inc., Citigroup, Oppenheimer & Co. Inc., Stifel Nicolaus Weisel, JMP Securities LLC, Roth Capital Partners, LLC, Brean Capital, LLC and Ladenburg Thalmann & Co. Inc. Burrill Securities LLC, Dawson James Securities, Inc., Maxim Group LLC, MLV & Co. LLC and Trout Capital LLC are acting as advisors to the Company. 

Company Quote

0.56 +3.50%
3:39pm EDT